Semaglutide

What Semaglutide Is

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist and the most extensively studied peptide in metabolic medicine. It is a 31-amino-acid analog of the human incretin hormone GLP-1 (7-37), engineered by Novo Nordisk with backbone substitutions and a C-18 fatty di-acid side chain that extend its half-life to roughly seven days and permit once-weekly subcutaneous dosing. Unlike most compounds tracked on this platform, semaglutide is a fully FDA-approved finished drug, not a research-use-only or compounded peptide. It is marketed as Ozempic (approved December 2017 for type 2 diabetes), Rybelsus (approved September 2019, the first oral GLP-1 tablet for type 2 diabetes), and Wegovy (approved June 2021 for chronic weight management), with an oral Wegovy formulation approved in December 2025.

Mechanism of Action

Semaglutide engages the GLP-1 receptor to reproduce the actions of the endogenous incretin hormone. On pancreatic beta cells it enhances glucose-dependent insulin secretion while suppressing glucagon from alpha cells, a glucose-dependent effect associated with a low intrinsic hypoglycemia signal in the trial record. It also slows gastric emptying and acts on hypothalamic and brainstem appetite circuits to reduce hunger and caloric intake, mechanisms studied as the primary drivers of weight loss. Its durability comes from deliberate engineering: an alpha-aminoisobutyric acid substitution at the DPP-4 cleavage site (position 8) resists enzymatic degradation, and a fatty-acid side chain acylated at Lys26 promotes strong albumin binding that slows renal clearance, together yielding the reported ~165-hour half-life.

What Published Research Has Examined

The clinical program is among the largest for any peptide, spanning three major trial families. The SUSTAIN program evaluated injectable semaglutide for glycemic control in type 2 diabetes. The PIONEER program tested the oral formulation. The STEP program investigated weight management in overweight or obese populations. These were later joined by dedicated cardiovascular-outcome trials, most notably SELECT, which studied cardiovascular risk in people with obesity but without diabetes. Additional published and ongoing research has extended into metabolic dysfunction-associated steatohepatitis, chronic kidney disease, and heart failure with preserved ejection fraction, reflecting broad interest in cardiometabolic applications.

Key Findings

STEP-1 (New England Journal of Medicine, 2021), a phase 3 trial in 1,961 adults, reported a mean body-weight reduction of approximately 14.9% with semaglutide 2.4 mg versus 2.4% with placebo over 68 weeks, with about half of participants losing at least 15% of body weight. SUSTAIN-6 (NEJM, 2016) reported fewer major adverse cardiovascular events in high-cardiovascular-risk type 2 diabetes (hazard ratio ~0.74). The landmark SELECT trial (NEJM, 2023), enrolling 17,604 adults aged 45 or older with overweight or obesity and established cardiovascular disease but no diabetes, reported roughly a 20% relative reduction in major adverse cardiovascular events, with separation from placebo emerging early in follow-up. These represent the highest tier of clinical evidence: large, randomized, placebo-controlled outcome trials.

Regulatory Status

Semaglutide is FDA Approved as a finished prescription drug across multiple indications and formulations. Because it is an approved medicine with defined labeling, it sits entirely outside the FDA Pharmacy Compounding Advisory Committee (PCAC) review of 503A bulk substances that governs investigational research peptides such as BPC-157, TB-500, KPV, MOTS-c, emideltide, epitalon, and semax. Semaglutide is not part of that compounding-bulks conversation and should not be conflated with Category 1 or Category 2 status. Alongside tirzepatide and bremelanotide (PT-141), it belongs to the small set of peptide-based agents that have completed full FDA approval.

Safety Considerations & Related Compounds

The most commonly reported effects in trials are gastrointestinal (nausea, vomiting, diarrhea, constipation), generally dose-dependent and most pronounced during escalation. Product labeling carries a boxed warning derived from rodent thyroid C-cell tumor findings of unestablished human relevance, and trials excluded people with a history of medullary thyroid carcinoma or MEN 2. The literature also notes pancreatitis and gallbladder signals, hypoglycemia risk in combination with other glucose-lowering agents, and areas of continued study including lean-mass reduction during rapid weight loss and reports of non-arteritic anterior ischemic optic neuropathy. Closely related compounds include the dual GIP/GLP-1 agonist tirzepatide and the earlier GLP-1 agonist liraglutide. All information here is educational and research-framed, not medical advice or dosing guidance.

Key published studies

Regulatory status

Current status: FDA Approved. FDA Approved. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.

Related compounds

Read our full guide on whether peptides are safe.